40 studies on Dulaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 40 dated studies on Dulaglutide. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
A study compared the efficacy and glycemic control effects of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents already using metformin.
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
This analysis highlights a critical shift in the clinical research paradigm for GLP-1 agonists in obesity, moving beyond primary weight loss to encompass a wider spectrum of metabolic and organ-specific benefits. Clin…
This methodological study is crucial for advancing the confidence and utility of real-world data in clinical research. Understanding the reliability of claims data emulation for cardiovascular outcomes could significa…
Understanding the detailed metabolome and lipidome shifts induced by retatrutide could provide critical insights into its multi-faceted benefits beyond simple weight loss and glycemic control. For peptide users and cl…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
This study's methodology establishes a crucial framework for comparing two significant obesity interventions—GLP-1 RAs and bariatric surgery—in the context of IBD management. For clinicians and patients navigating obe…
These findings are highly significant as they suggest tirzepatide offers superior kidney protection compared to dulaglagutide, a widely used GLP-1 agonist, in patients with Type 2 Diabetes. Given that chronic kidney d…
This comparative review is crucial for clinicians and patients in making informed treatment decisions, highlighting the distinct strengths of each medication. The findings underscore Tirzepatide's potent efficacy in w…
This study provides important reassurance regarding the cardiovascular safety profile of tirzepatide in a high-risk population. Given tirzepatide's superior efficacy in glycemic control and weight reduction, demonstra…
Understanding patient experience, especially regarding injection site pain, is crucial for improving adherence to long-term treatments for conditions like Type 2 Diabetes and obesity. If one GLP-1 agonist consistently…
This comprehensive systematic review solidifies the evidence for GLP-1 RAs as crucial therapeutic agents for cardiovascular protection, extending their benefits far beyond glucose control and weight management. These …
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
The successful completion of this early-phase trial is a significant step forward for IBI362, a novel therapeutic candidate for Type 2 Diabetes. This foundational data on its human safety, tolerability, and drug profi…
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
This comprehensive meta-analysis provides strong evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior glycemic control and weight loss benefits compared to Dulaglutide, a selective GLP-1 recep…
This network meta-analysis provides crucial evidence that could significantly impact clinical guidelines for managing Type 2 Diabetes patients with high cardiovascular risk. The identification of specific GLP-1 recept…
This study is critical because it directly addresses a common clinical scenario: how to optimize treatment for Type 2 Diabetes patients who may not be achieving their goals on existing GLP-1 RA therapy. The expected s…
As an active study (NCT07417618) not yet recruiting, specific results are not available; however, based on existing clinical trial data and the known mechanisms of these drugs, the study is expected to reveal signific…
This research highlights the superior patient experience and satisfaction associated with switching to Tirzepatide over escalating Dulaglutide in Type 2 Diabetes management. These findings provide crucial real-world e…
These findings are highly significant, establishing Tirzepatide as a potentially superior treatment option for individuals with Type 2 Diabetes who are at high risk for cardiovascular events. The dual benefits of subs…
This study provides crucial evidence for the comparative effectiveness of next-generation incretin therapies, offering valuable insights for clinicians. The findings suggest that Tirzepatide may be the preferred choic…
This study provides crucial evidence that tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior cardiovascular protection compared to the established GLP-1 receptor agonist dulaglutide in patients with type …
This comprehensive network meta-analysis provides crucial evidence for the comparative effectiveness of GLP-1 receptor and dual agonists in managing obesity. The findings strongly suggest that tirzepatide offers the m…
This study highlights that not all GLP-1 RAs are interchangeable regarding their safety profiles, providing crucial insights for personalized medicine. Clinicians can use this real-world evidence to make more informed…
This study provides compelling evidence that tirzepatide offers superior cardiorenal protection compared to dulaglutide, a well-established GLP-1 RA, in patients with type 2 diabetes and cardiovascular disease. This s…
This study provides compelling evidence supporting the clinical benefit of switching patients with inadequately controlled Type 2 Diabetes from dulaglutide to tirzepatide. The consistent efficacy observed across diver…
This comprehensive quantitative comparison provides invaluable evidence for clinicians and patients, offering clear guidance on the expected weight loss from different GLP-1 RAs. The findings underscore the varying po…
Free, no account — handy when you're working with Dulaglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account